Showing results (201-210 of 251) with videos related to
Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical featuresE Missiaglia, B Jacobs, G D'Ario, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialM H Kulke, P Ruszniewski, E Van Cutsem, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986C-H Köhne, E van Cutsem, J Wils, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancerJ-P Machiels, C Sempoux, P Scalliet, et al.British Journal of Cancer|February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD databaseC S Karapetis, H Liu, M J Sorich, et al.British Journal of Cancer|April 20, 2022
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 studyE Van Cutsem, I Danielewicz, M P Saunders, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.Pageof 26